Clinical remission in patients with systemic juvenile idiopathic arthritis treated with anti-tumor necrosis factor agents

Journal of Rheumatology

Volumn 36, Issue 5, 2009, Pages 1078-1082

  Russo, Ricardo A G ^a   Katsicas, María M ^a  

^a HOSPITAL DE PEDIATRÍA PROF DR JUAN P GARRAHAN   (Argentina)

Author keywords

Anti tumor necrosis factor agents; Etanercept; Juvenile systemic arthritis; Remission

Indexed keywords

ADALIMUMAB; ETANERCEPT; INFLIXIMAB; MEPREDNISONE; METHOTREXATE; ANTIRHEUMATIC AGENT; IMMUNOGLOBULIN G; MONOCLONAL ANTIBODY; TNFR FC FUSION PROTEIN; TNFR-FC FUSION PROTEIN; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR;

ADOLESCENT; ARTICLE; CHILD; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE ACTIVITY; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG ERUPTION; DRUG WITHDRAWAL; EYELID EDEMA; FEMALE; HUMAN; JUVENILE RHEUMATOID ARTHRITIS; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; QUESTIONNAIRE; REMISSION; THROMBOCYTE COUNT; TREATMENT OUTCOME; URTICARIA; WHEEZING; CLINICAL TRIAL; DRUG ANTAGONISM; DRUG COMBINATION; INFANT; PATHOPHYSIOLOGY; PRESCHOOL CHILD;

ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, JUVENILE RHEUMATOID; CHILD; CHILD, PRESCHOOL; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; IMMUNOGLOBULIN G; INFANT; MALE; METHOTREXATE; RECEPTORS, TUMOR NECROSIS FACTOR; REMISSION INDUCTION; TUMOR NECROSIS FACTOR-ALPHA;

EID: 67449094506     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: 10.3899/jrheum.090952     Document Type: Article

References (25)

1. Petty RE, Cassidy JT. Systemic arthritis. In: Cassidy JT, Petty RE, Laxer RM, Lindsley CB, editors. Textbook of pediatric rheumatology. 5th ed. Philadelphia: Elsevier Saunders; 2005:291-303.
2. Quartier P, Taupin P, Bourdeaut F, et al. Efficacy of etanercept for the treatment of juvenile idiopathic arthritis according to the onset type. Arthritis Rheum 2003;48:1093-101.
3. Kimura Y, Pinho P, Higgins G, et al. Treatment of systemic onset juvenile rheumatoid arthritis (SOJRA) with etanercept: A follow-up study [abstract]. Arthritis Rheum 2002;46 Suppl:S481.
4. Russo RAG, Katsicas MM, Zelazko M. Etanercept in systemic juvenile idiopathic arthritis. Clin Exp Rheumatol 2002;20:723-6.
5. Katsicas MM, Russo RAG. Use of infliximab in patients with systemic juvenile idiopathic arthritis refractory to etanercept. Clin Exp Rheumatol 2005;23:545-8.
6. Lovell DJ, Reiff A, Jones OY, et al. Long-term safety and efficacy of etanercept in children with polyarticular-course juvenile rheumatoid arthritis. Arthritis Rheum 2006;54:1987-94.
7. Wallace CA, Ruperto N, Giannini EH. Preliminary criteria for clinical remission for select categories of juvenile idiopathic arthritis. J Rheumatol 2004;31:2290-4.
8. van der Heijde DM, Klareskog L, Landewé R, et al. Disease remission and sustained halting of radiographic progression with combination etanercept and methotrexate in patients with rheumatoid arthritis. Arthritis Rheum 2007;56:3928-39.
9. Burmester GR, Ferraccioli G, Flipo RM, et al. Clinical remission and/or minimal disease activity in patients receiving adalimumab treatment in a multinational, open-label, twelve-week study. Arthritis Care Res 2008;59:32-41.
10. Horneff G, Schmeling H, Biedermann T, et al. The German etanercept registry for treatment of juvenile idiopathic arthritis. Ann Rheum Dis 2004;63:1638-44.
11. Prince FH, Twilt M, ten Cate R, et al. Long-term follow-up on effectiveness and safety of etanercept in JIA: the Dutch national register. Ann Rheum Dis 2008 Apr 15. [Epub ahead of print]
12. Petty RE, Southwood TR, Manners P, et al. International League of Associations of Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001. J Rheumatol 2004:31:390-2.
13. Moroldo MB, DeCunto C, Hubscher O, et al. Cross-cultural adaptation and validation of an Argentine-Spanish version of the Stanford Childhood Health Assessment Questionnaire (CHAQ). Arthritis Care Res 1998;11:382-90.
14. Giannini EH, Ruperto N, Ravelli A, Lovell DJ, Felson DT, Martini A. Preliminary definition of improvement in juvenile arthritis. Arthritis Rheum 1997;40:1202-9.
15. Cassidy JT, Petty RE. Chronic arthritis in children. In: Cassidy JT, Petty RE, Laxer RM, Lindsley CB, editors. Textbook of pediatric rheumatology. 5th ed. Philadelphia: Elsevier Saunders; 2005:206-60.
16. Pascual V, Allantaz F, Arce E, Punaro M, Banchereau J. Role of interleukin-1 (IL-1) in the pathogenesis of systemic onset juvenile idiopathic arthritis and clinical response to IL-1 blockade. J Exp Med 2005;20:1479-86.
17. Gattorno M, Piccini A, Lasiglie D, et al. The pattern of response to anti-interleukin-1 treatment distinguishes two subsets of patients with systemic-onset juvenile idiopathic arthritis. Arthritis Rheum 2008;58:1505-15.
18. Minden K, Niewerth M, Listing J, et al. Long-term outcome in patients with juvenile idiopathic arthritis. Arthritis Rheum 2002;46:2392-401.
19. Lomater C, Gerloni V, Gattinara M, Mazzotti J, Cimaz R, Fantini F. Systemic onset juvenile idiopathic arthritis: a retrospective study of 80 consecutive patients followed for 10 years. J Rheumatol 2000;27:491-6.
20. Oen K, Malleson PN, Cabral DA, Rosenberg AM, Petty RE, Cheang M. Disease course and outcome in juvenile rheumatoid arthritis in a multicenter cohort. J Rheumatol 2002;29:1989-99.
21. Fantini F, Gerloni V, Gattinara M, Cimaz R, Arnoldo C, Lupi E. Remission in juvenile chronic arthritis: a cohort study of 683 consecutive cases with a mean 10 year followup. J Rheumatol 2003;30:579-84.
22. Selvaag AM, Lien G, Sorskaar D, Vinje O, Forre O, Flato B. Early disease course and predictors of disability in juvenile rheumatoid arthritis and juvenile spondyloarthropathy: a 3 year prospective study. J Rheumatol 2005;32:1122-30.
23. Singh-Grewal D, Schneider R, Bayer N, Feldman BM. Predictors of disease course and remission in systemic juvenile idiopathic arthritis. Arthritis Rheum 2006;54:1595-601.
24. Yokota S, Imagawa T, Mori M, et al. Efficacy and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled, withdrawal phase III trial. Lancet 2008;371:998-1006.
25. Favalli EG, Areghini M, Arnoldi C, Panni B, Tosi S, Pontikaki I. Anti tumor necrosis factor α switching in rheumatoid arthritis and juvenile chronic arthritis. Arthritis Rheum 2004;51:301-2.